- Home
- APM vs MBRX Comparison
APM vs MBRX Comparison
Compare APM & MBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APM
- MBRX
- Stock Information
- Founded
- APM 2010
- MBRX 2015
- Country
- APM United Kingdom
- MBRX United States
- Employees
- APM N/A
- MBRX N/A
- Industry
- APM Biotechnology: Pharmaceutical Preparations
- MBRX Biotechnology: Pharmaceutical Preparations
- Sector
- APM Health Care
- MBRX Health Care
- Exchange
- APM Nasdaq
- MBRX Nasdaq
- Market Cap
- APM 18.9M
- MBRX 17.1M
- IPO Year
- APM 2018
- MBRX 2016
- Fundamental
- Price
- APM $1.85
- MBRX $0.38
- Analyst Decision
- APM
- MBRX Strong Buy
- Analyst Count
- APM 0
- MBRX 4
- Target Price
- APM N/A
- MBRX $5.00
- AVG Volume (30 Days)
- APM 20.3M
- MBRX 3.9M
- Earning Date
- APM 04-30-2025
- MBRX 08-12-2025
- Dividend Yield
- APM N/A
- MBRX N/A
- EPS Growth
- APM N/A
- MBRX N/A
- EPS
- APM N/A
- MBRX N/A
- Revenue
- APM N/A
- MBRX N/A
- Revenue This Year
- APM N/A
- MBRX N/A
- Revenue Next Year
- APM N/A
- MBRX N/A
- P/E Ratio
- APM N/A
- MBRX N/A
- Revenue Growth
- APM N/A
- MBRX N/A
- 52 Week Low
- APM $0.46
- MBRX $0.25
- 52 Week High
- APM $7.49
- MBRX $3.65
- Technical
- Relative Strength Index (RSI)
- APM 50.26
- MBRX 33.21
- Support Level
- APM $2.17
- MBRX $0.56
- Resistance Level
- APM $2.65
- MBRX $0.62
- Average True Range (ATR)
- APM 0.36
- MBRX 0.05
- MACD
- APM -0.05
- MBRX -0.03
- Stochastic Oscillator
- APM 18.38
- MBRX 9.25
About APM Aptorum Group Limited
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in one segment: research and development. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.
About MBRX Moleculin Biotech Inc.
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.